Clinical Trial Update: Efficacy of Vitex Agnus-castus BNO 1095 (20 mg) in Women With Primary Dysmenorrhea [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the efficacy of BNO 1095 (Vitex agnus-castus) for primary dysmenorrhea has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dysmenorrhea

Drugs mentioned

• BNO 1095 (Vitex agnus-castus)

Snippet

Sponsor: Bionorica SE | Conditions: Primary Dysmenorrhea | Phase 3 | Status: COMPLETED